Cerus Corporation: Q1 2023 Form 10-Q Summary
Business context and reporting period
Cerus Corporation is a blood-safety company focused primarily on the INTERCEPT Blood System for platelets, plasma and cryoprecipitation. The company also continues development of an INTERCEPT red blood cell system, which has not been commercialized. This filing covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022. Cerus operates in one segment: blood safety.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Product revenue | $31.0 million | $37.4 million | Down 17% |
| Government contract revenue | $7.5 million | $5.6 million | Up 35% |
| Total revenue | $38.5 million | $43.0 million | Down 11% |
| Gross profit on product revenue | $17.3 million | $19.4 million | Down 11% |
| Product gross margin | 56% | 52% | Up 4 percentage points |
| Research and development expense | $17.4 million | $14.1 million | Up 24% |
| SG&A expense | $21.6 million | $20.7 million | Up 4% |
| Loss from operations | $(14.1) million | $(9.8) million | Loss increased |
| Net loss attributable to Cerus | $(15.6) million | $(12.3) million | Loss increased |
| Basic and diluted loss per share | $(0.09) | $(0.07) | Loss increased |
| Net cash used in operating activities | $(8.5) million | $(21.5) million | Use decreased |
Product revenue declined primarily because of lower U.S. disposable platelet-system kit volumes and a weaker euro. Government contract revenue benefited from approximately $1.2 million of DoD revenue and a $0.7 million increase in BARDA revenue. The higher product margin reflected geographic and product mix, including a greater proportion of U.S. and platelet-kit sales.
R&D spending increased primarily because of next-generation illuminator development and higher clinical research activity. SG&A increased due to hiring, legal costs, commercialization efforts and stock-based compensation. Interest expense increased to $1.6 million from $1.4 million as borrowing costs rose.
Liquidity, debt and cash flow
- Cash and cash equivalents were $27.6 million at March 31, 2023, compared with $35.6 million at December 31, 2022.
- Short-term investments were $67.1 million, and restricted cash was $1.8 million, resulting in total cash, investments and restricted cash of $96.5 million versus $103.9 million at year-end 2022.
- Net cash used in operations was $8.5 million. Operating cash use benefited from collections of accounts receivable but was partially offset by inventory purchases.
- Total debt was $72.8 million at quarter-end, consisting of $18.0 million of current debt and $54.8 million of non-current term debt.
- On March 31, 2023, Cerus amended and restated its term loan and revolving credit facilities. The term loan carries a floating rate of Term SOFR, subject to a 1.00% floor, plus 6.50%; the stated rate at March 31, 2023 was approximately 11.3%.
- The amended term loan provides up to $75.0 million of term-loan capacity, including potential future tranches subject to conditions. The amended revolving facility initially provides up to $20.0 million and may be increased by up to $15.0 million with lender approval.
- Working capital was $84.6 million, up from $53.1 million at December 31, 2022, primarily because $41.5 million of debt was reclassified from current to long-term under the amended term loan.
- Management stated that available cash, short-term investments and expected cash receipts from product sales and government contracts should fund requirements for at least the next 12 months, although this conclusion depends on assumptions that may prove incorrect.
Material changes versus the prior comparable period
- Total revenue decreased 11%, despite a 35% increase in government contract revenue, because product revenue declined 17%.
- Operating loss widened by $4.3 million, and net loss attributable to Cerus increased by $3.3 million.
- R&D expense rose $3.3 million, while SG&A expense rose $0.8 million.
- Product gross margin improved from 52% to 56%, primarily due to sales mix and currency-related manufacturing-cost effects.
- Operating cash use improved by $13.0 million year over year, largely because of the timing of collections and payments.
- Inventory increased to $50.5 million from $44.5 million, including current inventory of $36.6 million, as Cerus built inventory to support expected demand and mitigate supply-chain risks.
- The company entered into amended debt facilities, extending the revolving facility maturity to March 1, 2028 and changing the classification of a substantial portion of term debt to non-current.
- BARDA committed an additional $33 million in March 2023, increasing committed funding to up to $181.9 million. Potential total funding could reach $278.9 million through September 2026 if additional options are exercised.
- Cerus received MDR certification for its INTERCEPT platelet system in March 2023. The plasma product’s MDR certification remained an important regulatory matter before expiration of its prior MDD-based certification.
Guidance, outlook, risks and unusual items
Management expects product revenue to grow in future periods, driven by platelet-business growth, increased market acceptance and adoption in additional geographies. The filing does not provide a specific numerical revenue or earnings forecast.
- Cerus expects continued operating losses and may never achieve profitability. Future funding depends substantially on product adoption, government contracts and access to equity or debt markets.
- The company has approximately $96.8 million available under its at-the-market equity sales agreement, but no shares were sold under the agreement during the quarter. Future equity issuance could dilute shareholders.
- BARDA funding is subject to milestones, government appropriations, option exercises and BARDA’s right to terminate for convenience. Up to $10 million of company co-investment may be required if certain options are exercised.
- The red blood cell system remains subject to clinical, manufacturing and regulatory risks. The timing of any European CE certification is uncertain, and U.S. development requires additional clinical data.
- Cerus relies heavily on third-party manufacturers, including Fresenius as the primary supplier of finished platelet and plasma disposable kits. Supply interruptions, component obsolescence, manufacturing non-conformities and limited alternate capacity could constrain sales.
- The current platelet-kit shelf life in the U.S. is limited to six months for products using a component manufactured with a new solvent, creating supply-chain and inventory risks.
- The company is developing a redesigned illuminator while managing potential obsolescence and limited availability of components for the current model.
- As of March 31, 2023, Cerus had $39.8 million of short-term and $7.0 million of long-term purchase commitments that were not recorded on the balance sheet.
- The company is responding to a civil investigative demand from the U.S. Department of Justice Antitrust Division concerning contracting and information-exchange practices. No claim or proceeding had been initiated as of the filing date, but the outcome and potential costs are uncertain.
- Product revenue is concentrated: American Red Cross represented 32% of product revenue and Établissement Français du Sang represented 15% in Q1 2023. Three customers represented approximately 68% of accounts receivable at quarter-end.
- Additional risks include regulatory approval and certification, clinical-trial delays, reimbursement and market adoption, foreign exchange, inflation, rising interest rates, cybersecurity, intellectual property, product liability and geopolitical conditions.
Most important facts for investors to verify
- Whether U.S. platelet-system volumes recover and whether product revenue growth materializes as management expects.
- Whether Cerus can reduce operating losses and cash consumption while continuing R&D and commercialization investments.
- The company’s ability to comply with debt covenants and manage approximately $72.8 million of debt at floating interest rates.
- Actual availability and timing of BARDA funding, achievement of required milestones and any required company co-investment.
- The timing and outcome of regulatory certification for the plasma system and red blood cell system.
- Progress on the redesigned illuminator, component obsolescence and manufacturing-capacity expansion.
- Customer concentration, renewal and purchase-volume trends, particularly for American Red Cross and EFS.
- The outcome, costs and potential business implications of the DOJ Antitrust Division investigation.
- Whether inventory levels, purchase commitments and product shelf-life limitations result in future write-downs, shortages or margin pressure.